Visomitin® (Vizomitin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspeye drops
Composition:
Composition per ml:
Active substance: Plastoquinonyl decyltriphenylphosphonium bromide (PDT) 0.155 μg
Excipients: Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.3 to 7.3, water for injection up to 1 ml.
Description:Transparent or slightly opalescent colorless or slightly colored liquid.
Pharmacotherapeutic group:Keratoprotective agent Antioxidant
ATX: & nbsp
  • Other drugs for the treatment of eye diseases
    • Pharmacodynamics:
    Plastoquinonyl decyltriphenylphosphonium bromide (PDTF) is a plastoquinone derivative which, through a linker chain (C10), is linked to a triphenylphosphine residue. PDT in low (nanomolar) concentrations shows high antioxidant activity. It also has a stimulating effect on the process of tear production, epithelization, and improves the stability of tear film.
    One of the reasons for the development of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photo-oxidation processes, leading to denaturation of the main structural component of the crystalline lens.The first protection of the eye tissues from ultraviolet radiation is a tear fluid that absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of tear fluid. According to the data of the preclinical study, the antiscaractal action of the drug Visomitin ® is associated with an increase in the level of expression of the main proteins of the crystalline lens, the restoration of the lens epithelium and the activation of energy processes in it. According to the clinical study, in patients with age-related cataracts using the drug Visomitin®, an increase in the antioxidant activity of tears was noted.
    Pharmacokinetics:Studies of pharmacokinetics in humans have not been conducted. In pre-clinical animal studies, the distribution of PDT in organs and tissues occurred within 48 hours after intravenous and intragastric administration. It was found that PDT is present in the largest concentrations in the tissues of the kidney, liver and heart for 1 hour after administration. PDT is relatively quickly subjected to enzymatic cleavage and covalent binding to proteins.
    Indications:Syndrome of "dry eye".The initial stage of age-related cataract.
    Contraindications:Hypersensitivity to the components of the drug, age to 18 years.
    Pregnancy and lactation:Adequate controlled studies in pregnant and breast-feeding women were not conducted. It is not recommended to prescribe the drug during pregnancy. If it is necessary to appoint during lactation for the period of treatment, breastfeeding should be discontinued.
    Dosing and Administration:"Dry Eye Syndrome": 1-2 drops of the drug in the conjunctival sac 3 times a day.The duration of the course of treatment is set by the doctor depending on the severity of the disease.The initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day The duration of the course of treatment is 6 months and during the treatment with the drug it is necessary to observe an ophthalmologist in order to assess the progression of the disease and the need to continue conservative therapy.
    Side effects:
    Allergic reactions.
    From the sense organs: possibly a brief burning sensation and rubbing in the eyes after instillation.
    Overdose:There is no evidence of overdose with topical application.
    Interaction:If necessary, it can be used simultaneously with other eye drops. In this case, the break between the installations should be at least 5 minutes.
    Effect on the ability to drive transp. cf. and fur:If after the application of the drug there is a brief blurriness of vision, it is not recommended to drive vehicles and engage in activities requiring high concentration of attention before recovery.
    Form release / dosage:Drops of eye concentration 0.155 μg / ml.
    Packaging:In polyethylene bottles of 5 ml with stoppers - droppers and screw-on caps. Each bottle with instructions for use is placed in a pack of cardboard.
    Storage conditions:In the dark place at a temperature of 2-8 ° C. The opened vial should be stored in a dark place at a temperature of 2-8 ° C; use within 1 month. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiry date printed on the package. The opened vial should be used within 1 month.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001355
    Date of registration:13.12.2011 / 19.01.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:MITOTEH, LLC MITOTEH, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp13.02.2017
    Illustrated instructions
      Instructions
      Up